Nakata K, Hiyama E, Katanoda K, Matsuda T, Tada Y, Inoue M, et al. Cancer in adolescents and young adults in Japan: epidemiology and cancer strategy. Int J Clin Oncol. 2022;27:7–15. https://doi.org/10.1007/s10147-021-02064-x.

Article  PubMed  Google Scholar 

Klein WMP, O’Connell ME, Bloch MH, Czajkowski SM, Green PA, Han PKJ, et al. Behavioral Research in Cancer Prevention and Control: Emerging Challenges and Opportunities. J Natl Cancer Inst. 2022;114:179–86. https://doi.org/10.1093/jnci/djab139.

Article  CAS  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33588.

Article  PubMed  Google Scholar 

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. https://doi.org/10.1016/bs.acr.2020.10.001.

Article  CAS  PubMed  Google Scholar 

Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250–61. https://doi.org/10.1016/j.jhep.2019.08.025.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37–49. https://doi.org/10.1038/s41575-022-00688-6.

Article  PubMed  Google Scholar 

Berardi G, Ratti F, Sposito C, Nebbia M, D’Souza DM, Pascual F, et al. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome. Hepatology. 2023;77:1527–39. https://doi.org/10.1097/hep.0000000000000027.

Article  PubMed  Google Scholar 

Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology. 2023;77:323–38. https://doi.org/10.1002/hep.32542.

Article  CAS  PubMed  Google Scholar 

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525–43. https://doi.org/10.1038/s41575-021-00438-0.

Article  PubMed  PubMed Central  Google Scholar 

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50. https://doi.org/10.1002/hep.29913.

Article  PubMed  Google Scholar 

Lleo A, Rimassa L, Colombo M. Hepatotoxicity of immune check point inhibitors: Approach and management. Dig Liver Dis. 2019;51:1074–8. https://doi.org/10.1016/j.dld.2019.06.017.

Article  CAS  PubMed  Google Scholar 

Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, et al. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol. 2021;12: 765101. https://doi.org/10.3389/fimmu.2021.765101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang G, Wang Q, Liang N, Xue H, Yang T, Chen X, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020;11:313. https://doi.org/10.1038/s41419-020-2509-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sas Z, Cendrowicz E, Weinhauser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci. 2022;23:3778. https://doi.org/10.3390/ijms23073778.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol. 2019;25:2977–89. https://doi.org/10.3748/wjg.v25.i24.2977.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu ZH, Yang DL, Wang L, Liu J. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol. 2021;12: 793343. https://doi.org/10.3389/fimmu.2021.793343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang Y, Chen P, Hu K, Dai G, Li J, Zheng D, et al. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. J Cell Mol Med. 2021;25:1568–82. https://doi.org/10.1111/jcmm.16256.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:92–7. https://doi.org/10.1093/nar/gkt1248.

Article  CAS  Google Scholar 

Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild AC, Tsay M, et al. mirDIP 41-integrative database of human microRNA target predictions. Nucleic Acids Res. 2018;46:D360–70. https://doi.org/10.1093/nar/gkx1144.

Article  CAS  PubMed  Google Scholar 

Zhang Q, Liu W, Zhang HM, Xie GY, Miao YR, Xia M, et al. hTFtarget: A Comprehensive Database for Regulations of Human Transcription Factors and Their Targets. Genomics Proteomics Bioinformatics. 2020;18:120–8. https://doi.org/10.1016/j.gpb.2019.09.006.

Article  PubMed  PubMed Central  Google Scholar 

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–12. https://doi.org/10.1038/nature08460.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–32. https://doi.org/10.1038/s41590-018-0044-z.

Article  CAS  PubMed  Google Scholar 

Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7:267. https://doi.org/10.1186/s40425-019-0749-z.

Article  PubMed  PubMed Central  Google Scholar 

Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol. 2020;11: 568759. https://doi.org/10.3389/fimmu.2020.568759.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–72. https://doi.org/10.1038/s41571-021-00573-2.

Article  CAS  PubMed  Google Scholar 

Li Z, Tuteja G, Schug J, Kaestner Klaus H. Foxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver Cancer. Cell. 2012;148:72–83. https://doi.org/10.1016/j.cell.2011.11.026.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang H, Wang Y, Huang T, Wang L, Liu Y, Wu Q, et al. FOXA2 inhibits doxorubicin-induced apoptosis via transcriptionally activating HBP rate-limiting enz